Saphnelo FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 3, 2021.
Saphnelo (anifrolumab) is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
- Limitations of Use: The efficacy of Saphnelo has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of Saphnelo is not recommended in these situations.
- Saphnelo is a first-in-class type I interferon receptor antibody.
- Most SLE patients have increased type I IFN signalling, which is associated with increased disease activity and severity. Saphnelo works by binding to subunit 1 of the type I IFN receptor, blocking the activity of type I IFNs.
- Saphnelo is administered via intravenous infusion over a 30-minute period every 4 weeks.
- Saphnelo can cause serious adverse reactions including serious Infections and hypersensitivity reactions. Common adverse drug reactions include nasopharyngitis, upper respiratory tract infections, bronchitis, infusion related reactions, herpes zoster and cough.
Development timeline for Saphnelo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.